Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Electro-acupuncture Plus PD-1 Inhibitors and Chemotherapy in Metastatic NSCLC
NCT07337096Recruiting
- Sponsor
- Guangzhou University of Chinese Medicine
- Start
- Jan 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Randomised trial in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Guangzhou University of Chinese Medicine. Primary endpoint: Progression-Free Survival up to 3 years. Started Jan 2026; status: recruiting.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07337096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07337096.